# Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

> **NCT00780598** · PHASE2 · COMPLETED · sponsor: **Chroma Therapeutics** · enrollment: 76 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- AML

## Interventions

- **DRUG:** Tosedostat

## Key facts

- **NCT ID:** NCT00780598
- **Lead sponsor:** Chroma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2012-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780598, "Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00780598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*